Adamas Pharmaceuticals reported 18.93M in Gross Profit on Sales for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 110.02M 8.15M
Aerie Pharmaceuticals AERI:US $ 21.01M 4.74M
Biocryst Pharmaceuticals BCRX:US $ 49.62M 36.44M
Flexion Therapeutics FLXN:US $ 23.2M 4.69M
GlaxoSmithKline GSK:LN 5.57B 566M
Glaxosmithkline GSK:US $ 5573M 566M
Gw Pharmaceuticals GWPH:US $ 140.66M 2.86M
Heron Therapeutics HRTX:US $ 7.92M 2.89M
Intra Cellular Therapies ITCI:US $ 18.01M 3.58M
Merk MRK:US $ 8718M 93M
Neurocrine Biosciences NBIX:US $ 285.8M 52.1M
Novartis NOVN:VX 9.54B 679M
Omeros OMER:US $ 28.48M 7.68M
Revance Therapeutics RVNC:US $ 13.38M 4.3M
Teva Pharmaceutical TEVA:IT 1.92B 4M
Zogenix ZGNX:US $ 17.57M 4.56M